Embla Medical Hf S/Adr (OSSUY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

At this time, I would like to welcome everyone to this emblematical Q4 and annual report for 2025 conference call. Today's call is being recorded. If you have any objections, please disconnect at this time. Throughout the presentation, all participants will be in a listen-only mode. Afterwards, there will be a question and answer session. To ask a question during the Q&A, please press 5-star on your telephone keypad. I'll now turn the call over to your speakers. You may now begin. Thank you very much, operator. Good morning, and welcome to the Ampla Medical conference call, where we will review the fourth quarter and full year results for 2025. I'm Sved Solvason, President and CEO of Ampla Medical. Today, also joining me here is our Chief Financial Officer, Artna Svensdottir, and Ampla Medical's Head of Investor Relations, Klaus Sintas. The presentation should take approximately 20 minutes, after which there will be an opportunity to ask questions during a Q&A session. If you can please go to the next slide. 2025 was a year of meaningful progress for Ample Medical, with several milestones as we continue to take steps on our journey to build a company that is focused on delivering products and services for individuals with a chronic as well as acute mobility need. The need for our solutions remains as strong as ever and once again our team delivered with focus and purpose. I want to take the opportunity to recap some of the key highlights on this slide. In September we completed the majority investment in Stryphonator. The investment marks a key milestone for Ampla Medical positioning us as a full range provider in the prosthetics market while strengthening our presence in key markets, especially private pay markets with less developed healthcare systems. In addition,...